Halberd Corporation (OTC:HALB) Stock Rallies 52% In A Week: What’s The Buzz?

There have been some stocks that have made considerable gains over the course of the past few days, and it may be a good time to take a closer look at some of them. One of the stocks that could be worth looking into at this point is Halberd Corporation (OTC:HALB), which clocked gains of as much as 52.15% over the course of the past five trading days. Additionally, the trading volume in the stock also went up 2.3 times its average. The stock also went past its 50-day moving average and set up a new uptrend after it crossed beyond the key trend line.

In this context, it could be a good move for investors to consider taking a look at the key developments from December 13, 2023. At the time, the company had announced that it had entered into an agreement with Canada-based CrodenHealth.com for the global distribution of Halberd Corporation’s patented naltrexone low-dose line of products.

The agreement had many other aspects, and one of those was that CrodenHealth.com was given the right of first refusal for rights of the same nature for future products in the Halberd pipeline. The chairman of the CrodenHealth.com board, Peter Croden, worked in the pharmaceutical industry for more than three decades in a number of senior management roles. Additionally, Todd Cohen, his nephew, and Brad Croden, his son, took the combined experience of the three to more than five decades.

Brad Croden, who is the Chief Executive Officer, noted that everyone at CrodenHealth.com was excited at the opportunity to monetize the current as well as future intellectual property of Halberd Corporation. He went on to state that the agreement laid the groundwork for a long and fruitful partnership that would be beneficial for both Halberd and CrodenHealth.com.